

## Supplemental Figure Legends

**Supplemental Figure 1a. Anti-CD8 $\beta$  depletes  $\alpha\beta$ CD8 $^{+}$  T cells but not  $\alpha\alpha$ CD8 $^{+}$  dendritic cells.** ProGP-1 pre-treated splenocytes were labelled with anti-CD8 $\beta$  followed by magnetic depletion as described in Methods. Staining with anti-CD3-FITC and anti-CD8 $\alpha$ -PE or anti-CD11c-FITC and anti-CD8 $\alpha$ -PE confirmed depletion of CD8 $\alpha\beta^{+}$  T cells but not CD8 $\alpha\alpha^{+}$  DCs.

**Supplemental Figure 1b. CD8 $^{+}$  T cell reconstitution is not impaired in recipients of wild-type grafts depleted of CD4 $^{+}$  T cells or  $J\alpha 18^{-/-}$  grafts.** Irradiated B6D2F1 mice received grafts consisting of whole spleen, CD4 $^{+}$  depleted spleen, CD8 $\beta^{+}$  depleted spleen or CD4 $^{+}$  and CD8 $\beta^{+}$  depleted spleen from wild-type donors. Additional cohorts received whole spleen from NKT cell deficient donors ( $J\alpha 18^{-/-}$ ) or CD4 $^{+}$  depleted spleen from wild-type donors supplemented with purified CD4 $^{+}$  T cells from wild-type or  $J\alpha 18^{-/-}$  donors. All donors were mobilized with ProGP-1. Total number of CD8 $^{+}$  T cells per spleen were determined at day +13 after SCT (WT whole spleen, n=9;  $J\alpha 18^{-/-}$  whole spleen, n=9; WT CD4 depleted spleen, n=9; WT CD8 $\beta$  depleted spleen, n=4; WT CD4 depleted spleen plus WT CD4 $^{+}$  T cells, n=5; WT CD4 depleted spleen +  $J\alpha 18^{-/-}$  CD4 $^{+}$  T cells, n=5). Combined data from 2 experiments. \*P < 0.05 vs WT whole spleen.

**Supplemental Figure 1c. Donor CD4 $^{+}$  T cells do not exert direct cytotoxicity against class II $^{+}$  LPS blasts.** Whole splenocytes from B6D2F1 (host-type) or C57BL6 (donor-type) mice were cultured with LPS at a final concentration of 25 $\mu$ g/ml. After 72 hours > 60% of cells recovered were B220 $^{+}$  Class II $^{+}$ . Irradiated B6D2F1 mice received whole spleen from wild-type donors mobilized with control diluent or ProGP-1. CD4 $^{+}$  T cells were sort-purified at day +13 and utilized as


effectors in  $^{51}\text{Cr}$  release CTL assays; Class II<sup>+</sup> LPS blast target population (ProGP-1 anti-host, n=4; ProGP-1 anti-donor, n=4; G-CSF anti-host, n=4; G-CSF anti-donor n=4).

**Supplemental Figure 1d. G-CSF plus Flt-3L expands donor DCs.** Wild-type donors were mobilized with G-CSF alone, G-CSF plus Flt-3L or ProGP-1 and absolute numbers of CD11c<sup>+</sup> class II<sup>+</sup> DCs per donor spleen determined (G-CSF, n=3; G-CSF + Flt-3L, n=3; ProGP-1 n=3). \*P < 0.05 vs G-CSF.


**Supplemental Figure 1e. Stem cell mobilization with Peg-G-CSF improves overall survival.** Irradiated B6D2F1 mice received whole spleen from wild-type donors mobilized with G-CSF or Peg-G-CSF. At the time of transplant, mice also received a leukemic challenge of  $5 \times 10^4$  P815. Overall survival by Kaplan-Meier analysis (G-CSF, n=18; Peg-G-CSF, n=18). \*P = 0.0007 G-CSF vs Peg-G-CSF

## Supplemental Figures


### Supplemental Figure 1a




### Supplemental Figure 1b



### Supplemental Figure 1c



### Supplemental Figure 1d



### Supplemental Figure 1e

